article Open AccessTop 1% cited
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
Journal of Hepatology · 2021 · Vol. 76(4) · pp. 862–873
Ann‐Lii Cheng✉(National Taiwan University Hospital)Shukui QinMasafumi Ikeda(National Cancer Center Hospital East)Peter R. Galle(Johannes Gutenberg University Mainz)Michel Ducreux(Institut Gustave Roussy)Tae‐You Kim(Seoul National University)Ho Yeong Lim(Samsung Medical Center)Masatoshi Kudo(Kindai University)В. В. Бредер(Russian Cancer Research Center NN Blokhin)Philippe Merle(Hôpital de la Croix-Rousse)Ahmed O. Kaseb(The University of Texas MD Anderson Cancer Center)Daneng Li(City of Hope)Wendy VerretNing MaAlan NicholasYifan Wang(Roche (China))Lindong Li(Roche (China))Andrew X. Zhu(Harvard University)Richard S. Finn✉(University of California, Los Angeles)
Hepatocellular Carcinoma Treatment and PrognosisCancer Mechanisms and TherapyCholangiocarcinoma and Gallbladder Cancer StudiesAtezolizumabBevacizumabMedicineSorafenibInternal medicineHazard ratioHepatocellular carcinomaOncologyPopulationClinical endpoint
MeSH terms
BevacizumabSorafenibAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, HepatocellularHumansLiver NeoplasmsAntibodies, Monoclonal, Humanized
Funding
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- Gilead Sciences
- F. Hoffmann-La Roche
- Exelixis
- Les Laboratories Pierre Fabre
- EA Pharma Co., Ltd.
- BeiGene
- Advanced Accelerator Applications
- Coherus Biosciences
- Bayer HealthCare
- Eisai
- Servier
- Ono Pharmaceutical
- Sun Pharma
- Ipsen
- Sirtex Medical
- Genentech
- Chugai Pharmaceutical
- Eli Lilly Japan
- Bayer Yakuhin
Citations
1,517
FWCI
119.29
field-weighted impact
References
18
Percentile
100%
vs. same field & year
Citations per year
References
Sorafenib in Advanced Hepatocellular Carcinoma
New England Journal of Medicine · 2008 · 12,835 citations
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
The Lancet · 2018 · 5,305 citations
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
CA A Cancer Journal for Clinicians · 2018 · 87,314 citations
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
New England Journal of Medicine · 2020 · 6,911 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.